BPCR — Biopharma Credit Cashflow Statement
0.000.00%
- $1.03bn
- $1.03bn
- $150.03m
- 79
- 81
- 85
- 97
Annual cashflow statement for Biopharma Credit, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Changes in Working Capital | 58.1 | 96.4 | 184 | 123 | 112 |
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | 58.1 | 96.4 | 184 | 123 | 112 |
| Other Investing Cash Flow Items | -47.5 | -94.8 | 48.2 | -1.66 | 39.1 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -47.5 | -94.8 | 48.2 | -1.66 | 39.1 |
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | -114 | -100 | -207 | -107 | -280 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -103 | -98.6 | 25.8 | 14.5 | -129 |